[Asia Economy Reporter Choi Dae-yeol] Cellma Therapeutics announced on the 3rd that it has decided to conduct a paid-in capital increase by issuing 125,470 shares through a third-party allotment method to raise approximately 1 billion KRW in operating funds.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing